143 related articles for article (PubMed ID: 2295068)
1. Synergistic interactions between cyclophosphamide or melphalan and VP-16 in a human rhabdomyosarcoma xenograft.
Lilley ER; Rosenberg MC; Elion GB; Colvin OM; Bigner DD; Friedman HS
Cancer Res; 1990 Jan; 50(2):284-7. PubMed ID: 2295068
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic analysis of melphalan-resistant human rhabdomyosarcoma xenograft TE-671 MR.
Lilley ER; Elion GB; Dewhirst MW; Schold SC; Blum MR; Savina PM; Laskowitz DT; Bigner DD; Friedman HS
Cancer Res; 1991 Aug; 51(15):3906-9. PubMed ID: 1855207
[TBL] [Abstract][Full Text] [Related]
3. Elevated DNA polymerase alpha, DNA polymerase beta, and DNA topoisomerase II in a melphalan-resistant rhabdomyosarcoma xenograft that is cross-resistant to nitrosoureas and topotecan.
Friedman HS; Dolan ME; Kaufmann SH; Colvin OM; Griffith OW; Moschel RC; Schold SC; Bigner DD; Ali-Osman F
Cancer Res; 1994 Jul; 54(13):3487-93. PubMed ID: 8012971
[TBL] [Abstract][Full Text] [Related]
4. Experimental chemotherapy of human medulloblastoma cell lines and transplantable xenografts with bifunctional alkylating agents.
Friedman HS; Colvin OM; Skapek SX; Ludeman SM; Elion GB; Schold SC; Jacobsen PF; Muhlbaier LH; Bigner DD
Cancer Res; 1988 Aug; 48(15):4189-95. PubMed ID: 3390813
[TBL] [Abstract][Full Text] [Related]
5. Hyperthermia-induced enhancement of melphalan activity against a melphalan-resistant human rhabdomyosarcoma xenograft.
Laskowitz DT; Elion GB; Dewhirst MW; Griffith OW; Savina PM; Blum MR; Prescott DM; Bigner DD; Friedman HS
Radiat Res; 1992 Feb; 129(2):218-23. PubMed ID: 1734453
[TBL] [Abstract][Full Text] [Related]
6. Experimental chemotherapy of human medulloblastoma with classical alkylators.
Friedman HS; Colvin OM; Ludeman SM; Schold SC; Boyd VL; Mulhbaier LH; Bigner DD
Cancer Res; 1986 Jun; 46(6):2827-33. PubMed ID: 3698009
[TBL] [Abstract][Full Text] [Related]
7. Acute in vivo resistance in high-dose therapy.
Teicher BA; Ara G; Keyes SR; Herbst RS; Frei E
Clin Cancer Res; 1998 Feb; 4(2):483-91. PubMed ID: 9516940
[TBL] [Abstract][Full Text] [Related]
8. Establishment of a melphalan-resistant rhabdomyosarcoma xenograft with cross-resistance to vincristine and enhanced sensitivity following buthionine sulfoximine-mediated glutathione depletion.
Rosenberg MC; Colvin OM; Griffith OW; Bigner SH; Elion GB; Horton JK; Lilley E; Bigner DD; Friedman HS
Cancer Res; 1989 Dec; 49(24 Pt 1):6917-22. PubMed ID: 2582434
[TBL] [Abstract][Full Text] [Related]
9. Melphalan: a potential new agent in the treatment of childhood rhabdomyosarcoma.
Houghton JA; Cook RL; Lutz PJ; Houghton PJ
Cancer Treat Rep; 1985 Jan; 69(1):91-6. PubMed ID: 3967262
[TBL] [Abstract][Full Text] [Related]
10. Synergy of irofulven in combination with other DNA damaging agents: synergistic interaction with altretamine, alkylating, and platinum-derived agents in the MV522 lung tumor model.
Kelner MJ; McMorris TC; Rojas RJ; Estes LA; Suthipinijtham P
Cancer Chemother Pharmacol; 2008 Dec; 63(1):19-26. PubMed ID: 18305940
[TBL] [Abstract][Full Text] [Related]
11. Melphalan transport, glutathione levels, and glutathione-S-transferase activity in human medulloblastoma.
Friedman HS; Skapek SX; Colvin OM; Elion GB; Blum MR; Savina PM; Hilton J; Schold SC; Kurtzberg J; Bigner DD
Cancer Res; 1988 Oct; 48(19):5397-402. PubMed ID: 3416297
[TBL] [Abstract][Full Text] [Related]
12. Lack of antitumour activity of human recombinant tumour necrosis factor-alpha, alone or in combination with melphalan in a nude mouse human melanoma xenograft system.
Furrer M; Altermatt HJ; Ris HB; Althaus U; Rüegg C; Liénard D; Lejeune FJ
Melanoma Res; 1997 Aug; 7 Suppl 2():S43-9. PubMed ID: 9578416
[TBL] [Abstract][Full Text] [Related]
13. Misonidazole enhancement of the action of BCNU and melphalan against human melanoma xenografts.
Clutterbuck RD; Millar JL; McElwain TJ
Am J Clin Oncol; 1982 Feb; 5(1):73-8. PubMed ID: 7081141
[TBL] [Abstract][Full Text] [Related]
14. Enhanced melphalan cytotoxicity following buthionine sulfoximine-mediated glutathione depletion in a human medulloblastoma xenograft in athymic mice.
Skapek SX; Colvin OM; Griffith OW; Elion GB; Bigner DD; Friedman HS
Cancer Res; 1988 May; 48(10):2764-7. PubMed ID: 3359437
[TBL] [Abstract][Full Text] [Related]
15. mTOR inhibition sensitizes gastric cancer to alkylating chemotherapy in vivo.
Cejka D; Preusser M; Fuereder T; Sieghart W; Werzowa J; Strommer S; Wacheck V
Anticancer Res; 2008; 28(6A):3801-8. PubMed ID: 19189667
[TBL] [Abstract][Full Text] [Related]
16. Paclitaxel, cisplatin, and cyclophosphamide in human ovarian cancer: molecular rationale and early clinical results.
Reed E; Kohn EC; Sarosy G; Dabholkar M; Davis P; Jacob J; Maher M
Semin Oncol; 1995 Jun; 22(3 Suppl 6):90-6. PubMed ID: 7541159
[TBL] [Abstract][Full Text] [Related]
17. TRAIL-induced cytotoxicity in a melphalan-resistant rhabdomyosarcoma cell line via activation of caspase-2.
Klüttermann K; Banning U; Kachel M; Krause C; Körholz D; Mauz-Körholz C
Anticancer Res; 2006; 26(1A):351-6. PubMed ID: 16475717
[TBL] [Abstract][Full Text] [Related]
18. Combination chemotherapy with a new folate analog: activity of 10-ethyl-10-deaza-aminopterin compared to methotrexate with 5-fluorouracil and alkylating agents against advanced metastatic disease in murine tumor models.
Schmid FA; Sirotnak FM; Otter GM; DeGraw JI
Cancer Treat Rep; 1987; 71(7-8):727-32. PubMed ID: 3607784
[TBL] [Abstract][Full Text] [Related]
19. Survival of hematopoietic and lymphoma colony-forming cells in vivo following the administration of a variety of alkylating agents.
Valeriote FA; Tolen SJ
Cancer Res; 1972 Mar; 32(3):470-6. PubMed ID: 4621955
[No Abstract] [Full Text] [Related]
20. Synergy of topotecan in combination with vincristine for treatment of pediatric solid tumor xenografts.
Thompson J; George EO; Poquette CA; Cheshire PJ; Richmond LB; de Graaf SS; Ma M; Stewart CF; Houghton PJ
Clin Cancer Res; 1999 Nov; 5(11):3617-31. PubMed ID: 10589779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
